27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Radius Health Inc (NASDAQ:RDUS) has multiple catalysts that could drive near-term upside in the shares of the company, according to Morgan Stanley.
Radius Health is an integrated biopharma company that specializes in therapies for osteoporosis, oncology and endocrine diseases.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Morgan Stanley analyst Matthew Harrison initiated coverage of the company with an Overweight rating and a $57 price target.
The Thesis
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, Harrison said in a Monday note.
Despite Eli Lilly and Co (NYSE:LLY)'s presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, Harrison said Tymlos' pricing is 40 percent lower than Forteo's — and convenience could help it grab share.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
"Key factors such as formulary wins with Express Scripts Holding Company (NASDAQ:ESRX) (9-12 percent of the market) and growing Medicare coverage (39 percent moving to 50-percent-plus in 2018) will accelerate the launch into 2H18," the analyst said.
Unlike the prevalent injectable therapies, the Radius patch could drive market growth, Harrison said. He estimates Radius could achieve 50 percent market share at peak, with $1 billion in peak sales in the late 2020s.
If the patch form of Tymlos succeeds, the analyst said the company can achieve $2 billion in peak sales, driving almost a four-fold potential return on Radius.
The consensus estimates for Radius have yet to account for the potential of elacestrant, a new agent for women who have not found success with prior breast cancer treatment, Harrison said.
The Price Action
Radius Health shares are down over 10 percent over the past year. Shares were up 3.07 percent at the time of publication Monday at $39.93.
Related Links:
Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer
What You Need to Know About Puma Biotech's 25% Slide
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.